Valuation Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2025-01-17 EST			5-day change	1st Jan Change
91.84 ^USD	+0.21%		+2.18%	-0.57%

01-15	Gilead Sciences, US government settle patent case over HIV prevention drugs	RE
01-13	Gilead to Seek M&A	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	82,209	73,031	91,081	107,677	100,942	114,457	114,457	-
Change	-	-11.16%	24.72%	18.22%	-6.25%	13.39%	0%	-
Enterprise Value (EV) ¹	82,450	103,910	118,530	126,522	118,665	132,534	127,939	122,759
Change	-	26.03%	14.07%	6.74%	-6.21%	11.69%	-3.47%	-4.05%
P/E ratio	15.4x	583x	14.7x	23.6x	18x	883x	15.8x	14.9x
PBR	3.65x	4.04x	4.32x	5.05x	4.48x	6.03x	5.23x	4.57x
PEG	-	-6x	0x	-0.9x	0.8x	-9x	0x	2.33x
Capitalization / Revenue	3.66x	2.96x	3.34x	3.95x	3.72x	4.04x	4.03x	3.91x
EV / Revenue	3.67x	4.21x	4.34x	4.64x	4.38x	4.68x	4.5x	4.19x
EV / EBITDA	6.61x	7.88x	8.12x	8.86x	9.01x	12.6x	8.92x	8.28x
EV / EBIT	7.45x	8.88x	9.45x	10.4x	11.3x	16.1x	10.2x	9.45x
EV / FCF	9.91x	13.8x	11x	15.2x	16x	16.3x	12.1x	11.3x
FCF Yield	10.1%	7.24%	9.12%	6.59%	6.25%	6.14%	8.28%	8.89%
Dividend per Share ²	2.52	2.72	2.84	2.92	3	3.065	3.232	3.39
Rate of return	3.88%	4.67%	3.91%	3.4%	3.7%	3.34%	3.52%	3.69%
EPS ²	4.22	0.1	4.93	3.64	4.5	0.104	5.8	6.17
Distribution rate	59.7%	2,720%	57.6%	80.2%	66.7%	2,947%	55.7%	54.9%
Net sales ¹	22,449	24,689	27,305	27,281	27,116	28,298	28,408	29,310
EBITDA ¹	12,468	13,184	14,598	14,283	13,177	10,519	14,345	14,826
EBIT ¹	11,064	11,704	12,548	12,180	10,484	8,235	12,501	12,989
Net income ¹	5,386	123	6,225	4,592	5,665	266.7	6,934	7,553
Net Debt ¹	241	30,879	27,449	18,845	17,723	18,076	13,482	8,302
Reference price ²	64.98	58.26	72.61	85.85	81.01	91.84	91.84	91.84
Nbr of stocks (in thousands)	1,265,146	1,253,528	1,254,384	1,254,244	1,246,042	1,246,266	1,246,266	-
Announcement Date	2/4/20	2/4/21	2/1/22	2/2/23	2/6/24	-	-	-

¹USD in Million²USD

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield	Capi. ($)
GILEAD SCIENCES, INC.	883.25x	4.68x	12.6x	+3.34%	114B
ELI LILLY AND COMPANY	57.77x	14.92x	41.72x	+0.72%	653B
JOHNSON & JOHNSON	21.23x	4.11x	12x	+3.24%	354B
NOVO NORDISK A/S	25.72x	9.14x	18.41x	+1.90%	353B
ABBVIE INC.	38.17x	6.45x	14.22x	+3.63%	303B
MERCK & CO., INC.	13.9x	4.23x	10.08x	+3.11%	248B
ROCHE HOLDING AG	15.8x	3.77x	9.81x	+3.71%	234B
ASTRAZENECA PLC	24.7x	4.3x	13.46x	+2.33%	207B
NOVARTIS AG	17.88x	4.15x	10.6x	+3.88%	195B
PFIZER, INC.	14.97x	3.29x	8.35x	+6.34%	149B
Average	111.34x	5.90x	15.12x	+3.22%	281.03B
Weighted average by Cap.	65.82x	7.49x	19.45x	+2.70%